Our results suggest new approaches to rescue diseases due to GATA-3 deficiency – such as in hypoparathyroidism, sensorineural deafness, and renal (HDR) syndrome – by OPG therapy. This evidence concerns the gene TNFRSF11B and sensorineural hearing loss disorder.